An investigation of raised plasma aspartate aminotransferase (AST) in marmosets after intramuscular ketamine injection suggested a local myotoxicity. This was confirmed by a range of histopathological findings from myofibrillar striation loss to necrosis. In addition to the elevations in AST levels, creatine kinase and the lactate dehydrogenase-S isoenzyme levels were elevated. It was further demonstrated that, although the physical properties of the injectable solution (pH, osmolality) and to a lesser extent the injection procedure itself caused slight changes in plasma enzyme levels, the ketamine was predominantly responsible for the lesion. No hepatic interactions were seen. This effect should be taken into consideration when this anaesthetic is used in the marmoset if the primary objectives of the experiment entail routine blood analyses.
is a rapidly acting dissociative anaesthetic used in medical and veterinary clinical practice and is generally very well tolerated. There is some evidence, however, to suggest that ketamine may lead to disturbances of hepatic and/or renal function in man (Roervik & Storner, 1974; Dundee et ai., 1980) and experimental animals (Meltzer, 1972; Madej & Stanczyk, 1975; D'Alleinne, 1982) . In addition, there have been reports that ketamine produces haematological changes in rhesus and vervet monkeys (Loomis, Henrickson & Received 24 February /986; ill revised form IO July /986. Accepted / September /986. Anderson, 1980; WalI, Worthman & Else, 1985) .
After using 20-30 mg/kg intramuscular ketamine (Vetalar: Parke Davis, Pontypool, Gwent) to anaesthetize marmosets, it was discovered that blood samples taken within 24 h of the injection showed elevations of plasma aspartate aminotransferase (AST). Alanine aminotransferase (ALT) and alkaline phosphatase were unaffected, indicating that the changes were unlikely to be related to hepatic effects.
Ketamine is used routinely as an anaesthetic in safety evaluation studies of novel pharmaceutical products in sub-human primates, and it could interfere with potential effects of the test compound.
It was therefore decided to investigate this finding further.
Materials and methods
Marmosets (Callithrix jacchus), about 2 years old, were housed either individualIy or in single sex pairs on wire grids in metal cages with external food hoppers and drinking bottles. The room was ventilated with a nominal 20 air changes hourly and controlIed at approximately 21°C. Animals were fed a mixture of chopped banana with whole pel-Ieted primate diet (Special Diet Services, Witham, Essex) and added orange juice with vitamin supplements; a quarter of a slice of brown bread was also offered on 3 days per week. Tap water was always available. Intramuscular or intravenous injections were performed using a needle directed into the gastrocnemius muscle or femoral vein respectively.
Blood samples were taken from the femoral vein using a 23 gauge needle into 2 ml heparinized tubes and plasma was separated for enzyme analysis.
The experimental procedure involved three phases: I, to evaluate the effect upon plasma enzyme levels statistically; II, to investigate the effects of the dosing procedure and route of administration;
III, to investigate the influence of pH and osmolality of the injectable solution on both enzyme levels and the histopathology at the injection site.
Phase I
A blood sample was taken from 24 marmosets for estimation of AST, isocitrate dehydrogenase (ICDH) and lactate dehydrogenase (LDH) (Davy, Jackson & Walker, 1984 
Statistical analysis
The statistical package used throughout was SAS (PROC. GLM). Preliminary analysis showed enzyme data to be non-gaussian and there was heterogeneity in the residual error at each sample time for each enzyme. These data were normalized using the log transformation before further analysis which consisted of a repeated measure analysis of variance to test for the effects of gender between marmosets and of time for each marmoset and a t test for residual effects at 192 h.
Phase II
The 24 animals from phase I were randomly 61 assigned to four groups (three males and three females per group). The results of the last blood sample in phase I (192 h) provided baseline data. Each group was treated as follows.
(1) In the control group the animals were removed from their cages, handled and replaced.
(2) Animals were dosed with 0·1 ml of 0·9% (wtlvol.) saline intramuscularly. (3) Animals were dosed with 0·1 ml Vetalar intramuscularly. (4) Animals were dosed with 0·1 ml Vetalar intravenously.
Blood samples were taken 24 hand 48 h post-treatment, and the plasma was assayed for AST, ICDH, LDH and CK.
Statistical analysis
The phase II data were analysed as a randomized design with repeated measures. The treatment and sex effects were estimated using the between-animal error whereas the effects of time and the interactions with time were estimated using the withinanimal error. The three degrees of freedom for the treatment effect were split into three contrasts with one degree of freedom each.
Phase III
A further 18 animals were divided into three groups (three males and three females per group) and a pre-dose blood sample was taken. They were then treated as follows:
(1) 0·1 ml citrate buffer (pH 7·4, osmolality 300 mOsmoUkg) intramuscularly; (2) 0·1 ml citrate buffer (pH 3·5, osmolality 730 mOsmoUkg) intramuscularly; (3) 0·1 ml Vetalar (pH 3·5, osmolality 730 mOsmoUkg) intramuscularly.
The injection sites were marked using a waterproof pen. Blood samples were taken 24 hand 48 h post-treatment for analysis of plasma AST, CK, LDH, ICDH and sorbitol dehydrogenase (SDH). SOH was analysed as described previously (Davy, Jackson & Walker, 1984) and was used as a liver-specific marker for hepatic damage as AL T levels are not totally specific to liver tissue in the marmoset (unpublished observations) .
After the 48 h blood sample, one male and one female from each group were killed and approximately 1 cm 3 of muscle around the injection site was removed into 10% buffered formal saline for histological examination.
Statistical methods
Plasma enzyme data were initially tested for normality and were transformed if necessary. These data were then submitted to an analysis of variance for each sample time, where the effects of treatment, gender (where appropriate) and their interaction were estimated. Gender effects were small for most enzymes and there was no evidence of any interaction between gender and treatment.
The final analyses involved estimation of the effects of treatm,ent alone for each time separately using analysis of variance. These data were then pooled and a repeated measure analysis of variance was used to estimate the overall effect of treatment between animals plus the effects of time and the interaction between time and treatment within animals.
Some enzymes showed significant differences between the groups before treatment in phase Ill. Analysis of covariance was used to adjust for these differences and to reduce the underlying variation at the later times. This analysis successfully reduced the residual mean square for AST, ALT and ICDH. Thus Davy, Trennery, Edmunds, Altman & Eichler treatment comparisons relate to the adjusted means for these enzymes in the separate time analyses.
In tables of results, confidence intervals (CIs) for data are presented in logarithm to the base 10 form. The geometric interval for any of the means was found by using lO[log(mean) + Cll for the upper limit and lO[log(mean) -Cll for the lower limit.
Results
The differences in plasma enzyme levels seen after ketamine treatment in phase I are shown in Table 1 . All enzyme levels were significantly elevated but AST and CK were particularly affected. Statistically significant but minor changes in plasma ICDH probably reflect the variable nature of the levels of this enzyme and are unlikely to be a function of the ketamine treatment (see below).
The isoenzyme pattern for LDH showed an increase in the proportion of LDH-5 (Table 2) . LDH-5 is predominantly present in muscle and liver. Because of the lack of an effect on SOH, which is virtually liver specific, and the massive (tenfold) elevation in plasma CK, it is probable that the increases in plasma AST were a result of muscular damage. At 192 h after treatment, only ICOH levels demonstrated a residual effect (P = 0·023) but individual values were well within our reference intervals (Davy, Jackson & Walker, 1984) .
The results of phase II are shown in Table 3 and show that the tissue damage that resulted in elevated plasma AST and CK levels was a direct effect of ketamine at the intramuscular injection site. Ketamine when administered as a single bolus intravenous injection failed to show any significant increase in the plasma enzyme levels. The statistical analyses are also presented in Table 3 and do not confirm the 
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elevated LDH levels seen in phase 1,24 h after a single intramuscular dose of ketamine. The effect of mechanical damage from the intramuscular injection procedure itself (saline control) can be seen from the smaller increases in CK and AST levels.
In phase III we examined the influence of pH or osmolality effects at the site of injection. The group mean enzyme levels attained with a summary of the statistical analysis are presented in Table 4 and reveal the following points of interest.
(i) Intramuscular injection of ketamine was the main cause of the increase in plasma CK and AST (P < 0·001). However, the slight rise (P > 0·2) at 6 h was probably associated with the injection procedure and low pH, high osmolality.
(ii) Plasma LDH was also affected by keta- CI (loglO) 0·583 0·583 0·583 11 = 6 (three males, three females) for each treatment group. The CIs were obtained from repeated measure analysis and are therefore the same for each mean. i.m., intramuscular; Lv., intravenous. "From repeated measure analysis of variance on treatment contrasts. mine treatment 6 h post-treatment (P < 0·003). This had not been seen in phases I or II as levels were returning to 'normal' by 24 h.
(iii) The lack of significant elevations in SOH confirms that the liver was not involved in the elevations in plasma AST and that overall it was unaffected by the acute intramuscular administration of ketamine at "the dose level employed.
As may be seen from Table 5 the histopathological assessment of the injection sites of two animals (one male and one female) from each group demonstrates the morphological features of the ketamine lesion to be uneven staining of sarcoplasm, loss of striations (Fig. 2) , shrinkage of muscle fibres and in one case a degree of hyalinization and necrosis (Fig. 1 ). In addition there was evidence of There was no muscle damage in control animals injected with saline at pH 7·4 and osmolality 300 mOsmol/kg.
Discussion
A rise in plasma AST has been found after intramuscular administration of ketamine to marmosets during safety screening procedures and this study demonstrated a local myotoxic response at the injection site. Plasma enzyme analysis confirms that the toxic effect of the intramuscular administration of ketamine is restricted principally to local muscle fibre damage. The study further demonstrated that the physical properties of the compound (low pH, high osmolality) were partly responsible for the changes in plasma AST, CK and LDH. This finding is in agreement with earlier work on the intramuscular administration of hyperosmolar solutions (Sidell, Culver & Kaminskis, 1974) and drugs with a pH lower than physiological values (Andersen & Damsgaard, 1976) . Zener and Harrison (1974) reported raised CK levels in patients receiving intramuscular lignocaine. This could have been a hyperosmolar effect (660 mOsmoVkg) as the increase by a factor of 3-4 was in line with the low pH, high osmolality saline results in phase III.
The changes seen here, however, were predominantly due to the molecules of ketamine themselves with only a partial effect caused by their physical properties in solution.
The results of phase II of this experiment show that ketamine may be administered intravenously to attain equivalent anaesthesia without altering circulating enzyme levels. However, it should be noted that ketamine at higher intravenous dose levels can be hepatotoxic (Madej & Stanczyk, 1975; Dundee et ai., 1980; D'Alleinne, 1982) . Thus the local myotoxic response and associated release of enzymes into plasma up to 48 h after intramuscular ketamine injection should be taken into consideration when using this anaesthetic if the primary objectives of the experiment entail any routine blood analyses.
